{"id":"zoster-vaccine-recombinant","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site erythema"},{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Myalgia"},{"rate":"25-35","effect":"Fatigue"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":{"setId":"c46e8702-5680-462b-a093-0c7720f77020","title":"SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) INJECTION, SOLUTION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant VZV glycoprotein E (gE) combined with an AS01B adjuvant system that enhances immune response. It works by priming both CD8+ T cells and antibody-producing B cells against VZV, providing durable protection against reactivation of latent virus that causes shingles and post-herpetic neuralgia.","oneSentence":"This recombinant zoster vaccine stimulates the immune system to prevent herpes zoster (shingles) by inducing varicella-zoster virus (VZV)-specific cell-mediated and humoral immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:59:22.408Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of post-herpetic neuralgia"}]},"trialDetails":[{"nctId":"NCT06162494","phase":"PHASE4","title":"Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-03-18","conditions":"Varicella Zoster","enrollment":80},{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07321808","phase":"","title":"Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-05-16","conditions":"Immunocompromised Patients","enrollment":300},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT05775718","phase":"PHASE2","title":"Shingrix In Recipients of Allogeneic Transplants","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-10-24","conditions":"Bone Marrow Transplant, Stem Cell Transplant","enrollment":55},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05811754","phase":"","title":"Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-05-09","conditions":"Herpes Zoster","enrollment":2844},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT05898464","phase":"PHASE4","title":"Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-06-27","conditions":"Vaccination; Infection, Vaccine Adverse Reaction","enrollment":150},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05575830","phase":"PHASE4","title":"Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calmy Alexandra","startDate":"2022-12-14","conditions":"RZV Vaccine (Shingrix ®)","enrollment":225},{"nctId":"NCT05550194","phase":"PHASE4","title":"VZV in the Enteric Nervous System: Pathogenesis and Consequences","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-27","conditions":"Achalasia","enrollment":40},{"nctId":"NCT04403139","phase":"PHASE4","title":"VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-04-27","conditions":"Varicella Zoster Virus Infection","enrollment":50},{"nctId":"NCT03798691","phase":"PHASE4","title":"Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-28","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":33},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06262776","phase":"NA","title":"Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Central Adelaide Local Health Network Incorporated","startDate":"2024-03-20","conditions":"Immunosuppression, Vaccine Response Impaired","enrollment":120},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT04869982","phase":"PHASE4","title":"Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-14","conditions":"Herpes Zoster","enrollment":6138},{"nctId":"NCT05991427","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-11-07","conditions":"Herpes Zoster","enrollment":65},{"nctId":"NCT06654700","phase":"PHASE3","title":"Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-12-09","conditions":"Herpes Zoster","enrollment":1200},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT06137755","phase":"PHASE1","title":"Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above","status":"RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2023-03-15","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":32},{"nctId":"NCT06447779","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-07-13","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT06334861","phase":"","title":"Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-06-23","conditions":"Herpes Zoster","enrollment":178},{"nctId":"NCT06224270","phase":"PHASE4","title":"Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2024-10","conditions":"Inflammatory Bowel Diseases, IBD","enrollment":""},{"nctId":"NCT04748939","phase":"PHASE4","title":"Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT","status":"NOT_YET_RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2025-01","conditions":"Herpes Zoster","enrollment":140},{"nctId":"NCT04047979","phase":"PHASE2","title":"Systems Biology of Zoster Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-14","conditions":"Zoster, Zoster Varicella, Shingles","enrollment":38},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT06364033","phase":"NA","title":"Biological and Clinical Efficacy of Shingrix in Patients With CLL","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-08","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL","enrollment":312},{"nctId":"NCT05596526","phase":"PHASE4","title":"Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients","status":"RECRUITING","sponsor":"Prof Patrice Lalive","startDate":"2022-12-01","conditions":"Shingles, Zoster","enrollment":100},{"nctId":"NCT03771157","phase":"EARLY_PHASE1","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)","enrollment":33},{"nctId":"NCT05924685","phase":"PHASE4","title":"PREPARE-iVAC Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2023-08-22","conditions":"COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response","enrollment":110},{"nctId":"NCT05769049","phase":"PHASE1","title":"The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2023-02-09","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT03993717","phase":"","title":"Solid Organ Transplant SHINGRIX","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-30","conditions":"Kidney Transplant; Complications","enrollment":2},{"nctId":"NCT05371080","phase":"PHASE3","title":"A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-08-10","conditions":"Herpes Zoster","enrollment":3038},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT05750017","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-03-23","conditions":"Herpes Zoster, Vaccine-Preventable Diseases","enrollment":66},{"nctId":"NCT05554068","phase":"PHASE2","title":"Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","status":"RECRUITING","sponsor":"Loyola University","startDate":"2023-03-07","conditions":"Shingles","enrollment":100},{"nctId":"NCT05718037","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-08-01","conditions":"Herpes Zoster","enrollment":40},{"nctId":"NCT05705180","phase":"","title":"The Influence of Trained Immunity in COVID-19 Vaccinated Individuals","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2022-12-01","conditions":"Zoster Varicella, Vaccination; Infection","enrollment":600},{"nctId":"NCT04516408","phase":"NA","title":"Recombinant Zoster Vaccine in Stable SLE Patients","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-04-20","conditions":"Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus","enrollment":464},{"nctId":"NCT03493776","phase":"PHASE4","title":"Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation","status":"UNKNOWN","sponsor":"Deepali Kumar","startDate":"2018-04-15","conditions":"Varicella Zoster Vaccine","enrollment":50},{"nctId":"NCT03685682","phase":"PHASE3","title":"Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-05-25","conditions":"Varicella Zoster Vaccine","enrollment":23},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160},{"nctId":"NCT01064141","phase":"PHASE2","title":"A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Shingrix"],"phase":"marketed","status":"active","brandName":"Zoster Vaccine Recombinant","genericName":"Zoster Vaccine Recombinant","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This recombinant zoster vaccine stimulates the immune system to prevent herpes zoster (shingles) by inducing varicella-zoster virus (VZV)-specific cell-mediated and humoral immunity. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}